Sources: CME Clearing advisory 26-370: CORE support for securities clearing; CME Group: A Primer on Margining Styles for Options
What the November 11 notice establishes
Status
| Category | Status |
|---|---|
| Test environment | Available to entitled users |
| Production | Expected later in November |
| Futures / securities cross-margin | Not supported by CORE |
Sources: [1] CME Clearing advisory 26-370: CORE support for securities clearing · 2026-11-11; test availability and prospective November production
CHICAGO
CME Clearing's November 11 advisory says CORE margin-calculator support for CME Securities Clearing contracts is available in its test environment to appropriately entitled users. Production availability was expected later in November, with a further advisory after launch. Despite the notice title's use of “Live,” the body explicitly distinguishes testing from production. [1]
A crucial boundary
The advisory also says CORE does not support cross-margin workflows between CME futures and CME Securities Clearing. It directs users to the applicable access arrangements for the securities-clearing service. This report therefore makes no claim that a combined futures-and-cash portfolio already receives an operational margin offset through the new calculator. [1]
ACTA analysis: a calculation is only one layer
A risk model estimates potential exposure from a defined portfolio and set of assumptions. Operational margin depends additionally on which accounts hold the positions, which legal agreements apply, which products qualify and whether the required collateral is available. A calculator can help evaluate a proposed trade, but its output cannot establish that an unapproved account structure is eligible for the same treatment. The implementation boundary belongs in the trading decision, not in a footnote discovered afterward.
Separate the two cash questions
CME's standing educational material explains that options can use different margining styles and that futures-style options involve realized variation margin. [2] More generally, an analyst should separate collateral posted against potential future exposure from cash exchanged as positions are revalued. A portfolio may have a manageable estimated risk charge yet require substantial cash at an inconvenient time. Neither the initial deposit nor notional principal is a complete measure of its financing needs.
What testing should establish
A useful test portfolio includes the actual identifiers, quantities, maturities and account classifications intended for production. It should exercise exceptions as well as ordinary inputs: missing prices, expired contracts, unsupported products and rejected permissions. The output needs a reproducible explanation. If a change in a model or input produces a material difference, a desk must be able to identify the cause before relying on it in a live collateral forecast.
Do not infer a volatility event
A technology notice is not evidence of losses at a clearinghouse or unusual stress among its members. Nor does the availability of an additional calculator establish lower costs for every participant. The concrete development this week is a stated testing capability with explicit exclusions. Its financial significance lies in how firms can prepare their risk and collateral operations, rather than in any invented market move.
ACTA analysis: permission is part of the specification
A production workflow needs a precise statement of who can submit which portfolio for which account. An estimate generated with a test entitlement may be useful for software validation without authorizing a live operation. The same caution applies to saved examples: a sample portfolio can prove that a connection works, but it cannot prove that a customer’s actual positions are eligible. Firms should retain the assumptions behind each result and reconcile the approved account structure before using it to allocate collateral. When those details are missing, the responsible conclusion is that the estimate is provisional. That conclusion leaves room for the new capability to be useful while preventing a test result from becoming an unsupported funding commitment.
Sources & methodology
Bracketed numbers refer to the sources below. Analysis is original editorial interpretation, not a personalized recommendation.
- CME Clearing advisory 26-370: CORE support for securities clearing · 2026-11-11; test availability and prospective November production
- CME Group: A Primer on Margining Styles for Options · Standing educational background; not a current margin-rate notice
